我國國產平價抗肺癌藥伊瑞可上市

A generic targeted drug to treat cancer manufactured by a Chinese pharmaceutical company hit market recently.

我國製藥公司生產的一種仿製靶向抗癌藥物於日前上市。

The new gefitinib cancer-treating drug, whose Chinese commercial name is Yiruike, was produced by Qilu Pharmaceutical (Qilu).

這款新上市的吉非替尼抗癌藥由齊魯製藥研製，中文名是伊瑞可。

Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.

伊瑞可的上市結束了易瑞沙在國內市場近10年的壟斷。易瑞沙由英國跨國生物製藥公司阿斯利康研製，於2005年引入國內。

Yiruike was approved for marketing by the China Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu said.

齊魯製藥稱，易瑞沙的專利保護於2016年4月到期後，國家食品藥品監督管理總局批准伊瑞可上市。

Qilu's general manager Li Yan said Yiruike, at less than RMB2,000 a pack, is a fraction of the price of the previously available drug, meaning more people in need can be helped.

齊魯製藥總經理李燕稱，伊瑞可的售價不到2000元/盒，是此前能買到的藥物的價格的一小部分，這意味着更多有需要的人可以得到幫助。

Gefitinib is a much-needed first line medicine used in targeted therapies against non-small-cell lung cancer, which accounts for about 80% of lung cancer cases in China.

吉非替尼是靶向治療非小細胞肺癌的急需一線藥物，非小細胞肺癌約佔我國肺癌病例總數的80%。

Lung cancer kills more people than any other cancer in China. About 591,000 people die from lung cancer in China every year, according to the national cancer center. There are about 733,000 new cases every year.

在中國，肺癌的致死人數要多於其他任何癌症。根據國家癌症中心的數據顯示，每年我國大約會有59.1萬人因肺癌去世，此外每年還會有73.3萬的新增病例。